Resolution of systemic complications in Schistosoma mansoni-infected mice by concomitant treatment with praziquantel and Schisandrin B |
| |
| Institution: | 1. Department of Biochemistry, School of Medicine, Tzu Chi University, Hualien, Taiwan;2. Institute of Medical Sciences, Tzu Chi University, Hualien, Taiwan;3. Department of Molecular Parasitology and Tropical Diseases, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan;4. Center for International Tropical Medicine, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan;1. National Animal Protozoa Laboratory & College of Veterinary Medicine, China Agricultural University, Beijing 100193, China;2. Institute of Animal Science, Chinese Academy of Agricultural Sciences, Beijing 100193, China;3. Department of Veterinary Pathobiology, College of Veterinary Medicine & Biomedical Sciences, Texas A&M University, College Station, TX 77843, USA;4. Department of Pathobiology, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA;1. Department of Botany and Zoology, Faculty of Science, Masaryk University, Brno, Czech Republic;2. Hasselt University, Centre for Environmental Sciences, Research Group Zoology: Biodiversity & Toxicology, Diepenbeek, Belgium;3. Institute of Biology, University of Graz, Universitätsplatz 2, A-8010 Graz, Austria;1. Department of Life Sciences, Natural History Museum, Cromwell Road, London SW7 5BD, UK;2. The University of Queensland, School of Biological Sciences, St Lucia, Queensland 4072, Australia;1. Department of Veterinary Microbiology & Pathology, Washington State University, P.O. Box 647040, Pullman, WA 99164, USA;2. Animal Disease Research Unit, Agricultural Research Service, US Department of Agriculture, P.O. Box 646630, Pullman, WA 99164, USA |
| |
| Abstract: | Schistosomiasis is a tropical parasitic disease, in which the major clinical manifestation includes hepatosplenomegaly, portal hypertension, and organs fibrosis. Clinically, treatment of schistosomiasis involves the use of praziquantel (PZQ) and supportive care, which does not improve the patient’s outcome as liver injuries persist. Here we show the beneficial effects of using PZQ in combination with Schisandrin B (Sch B). Concomitant treatment with PZQ and Sch B resulted in a significant improvement of hepatosplenomegaly and fibrosis, compared with single-agent treatment. We also demonstrated that PZQ-Sch B treatment ameliorates injuries in the lungs and intestine better than the sole use of PZQ or Sch B. In addition, PZQ-Sch B treatment improves the survival of S. mansoni-infected mice, and the treatment combination yields better therapeutic outcomes, as indicated by a partial improvement in neurological function. These results were accompanied by a reduction in neurological injuries. Collectively, we suggest that PZQ-Sch B concomitant therapy may be useful to alleviate schistosomiasis-associated liver injuries and prevent systemic complications. |
| |
| Keywords: | Schistosomiasis Praziquantel Schisandrin B Concomitant therapy Fibrosis |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
